Lancet
-
Randomized Controlled Trial Clinical Trial
Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
New vaccines are needed to prevent cholera caused by Vibrio cholerae O139. Attenuated V cholerae O139 vaccines were made by deleting multiple copies of the cholera-toxin genetic element from two virulent strains of the organism, MO10 and AI4456. The deletion mutants were further modified by insertion of a construct that encoded the B subunit of cholera toxin, thus generating strains Bengal-3 and VRI-16. ⋯ By contrast, 1 of 7 vaccinees had diarrhoea, which was mild and had a long incubation period. Vaccine protective efficacy was 83%. Our results indicate the Bengal-15 is a safe live attenuated vaccine candidate for cholera caused by the O139 serogroup.
-
Letter Randomized Controlled Trial Clinical Trial
Effect of sulindac on small polyps in familial adenomatous polyposis.